Schizophrenia as a membrane lipid disorder which is expressed throughout the body

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 3-7

  Horrobin, David F ^a  

^a Scotia Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE PHOSPHOLIPID; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PHOSPHOLIPASE A;

ARACHIDONIC ACID METABOLISM; BRAIN; CELL MEMBRANE; CONFERENCE PAPER; DOPAMINERGIC SYSTEM; FEVER; HUMAN; HYPOTHESIS; INFLAMMATORY DISEASE; LIPID ANALYSIS; PAIN; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE;

EID: 0029742284     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90138-6     Document Type: Conference Paper

References (46)

1. Witt M. R., Nielsen M. Characterization of the influence of unsaturated free fatty acids on brain GABA/benzodiazepine receptor binding in vitro. J Neurochem 1994; 62: 1432-1439.
2. Horrobin D. F. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; 1: 936-937.
3. Horrobin D. F., Ally A. I., Karmali R. A., Karmazyn M, Manku M. S., Morgan R. O. Prostaglandins and schizophrenia: further discussion of the evidence. Psychol Med 1978; 8: 43-48.
4. Horrobin D. F. Schizophrenia: reconciliation of the dopamin, prostaglandin and opioid concepts and the role of the pineal. Lancet 1979; i: 529-531.
5. Horrobin D. F. Schizophrenia. In: Cohen M. M., eds. Biological Protection with Prostaglandins. Vol 1. Boca Raton: CRC Press, 1985: 254-262.
6. Horrobin D. F. Essential fatty acids, prostaglandins and schizophrenia. In: Stafanis, C. N., ed. Psychiatry: A World Perspective. Vol 2. Amsterdam: Elsevier, 1990: 140-144.
7. Horrobin D. F. The relationship between schizophrenia and essential fatty acids and eicosanoid production. Prostaglandins Leukot Essent Fatty Acids 1992; 46: 71-77.
8. Horrobin D. F., Glen A. I. M., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr Res 1994; 13: 195-207.
9. Vinogradov S., Gottesman I. I., Moises H. W., Nicol S. Negative association between schizophrenia and rheumatoid arthritis. Schizophr Bull 1991; 17: 669-678.
10. Holden R. J. The estrogen connection: the etlological relationship between diabetes, cancer, rheumatoid arthritis and psychiatric disorders. Med Hypotheses 1995; in press.
11. Holden R. J., Mooney P. A. Schizophrenia is a diabetic brain state: an elucidation of impaired neurometabolism. Med Hypotheses 1995; 43: 420-435.
12. Davis G. C., Buchsbaum M. S., van Kammen D. P., Bunney W. E. Analgesia to pain stimuli in schizophrenics and its reversal by naltrexone. Psychiatr Res 1979; 1: 61-69.
13. Lipper S., Werman D. S. Schizophrenia and intercurrent physical illness: a critical review of the literature. Comprehens Psychiatr 1977; 18: 11-22.
14. Murray R. M., O'Callaghan E., Castle D. J., Lewis S. W. A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 1992; 18: 319-332.
15. Susser E., Lin S. P. Schizophrenia after prenatal exposure to the Dutch hunger winter of 1944-1945. Arch Gen Psychiatr 1992; 29: 983-988.
16. McNeil T. F., Cantor-Graae E., Nordstrom L. G., Rosenlund T. Head circumference in 'preschizophrenic' and control neonates. Br J Psychiatr 1993; 162: 517-523.
17. Rifkin L., Jones P., Murray R. M. Low birth weight and poor premorbid childhood function predict cognitive impairment in schizophrenia. Schizophr Res 1993; 9: 138-139.
18. Wahl O. F., Hunter J. Are gender effects being neglected in schizophrenia research? Schizophr Bull 1992; 18: 313-317.
19. World Health Organization. Schizophrenia: An International Follow-Up Study. New York: Wiley, 1979.
20. Horrobin D. F. Niacin flushing, prostaglandin E and evening primrose oil. A possible objective test for monitoring therapy in schizophrenia. J Orthomo Psychiatr 1980; 9: 33-34.
21. Rybakowski J., Weterle R. Niacin test in schizophrenia. Biol Psychiatr 1991; 29: 834-836.
22. Hudson C. J., Lin A., Cogan S., Warsh J. J. Clinical detection of altered prostaglandin function in a schizophrenia sub-type. Schizophr Res 1995; 15: 60.
23. Glen A. I. M., Glen E. M. T., Horrobin D. F. et al. A red cell abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12: 53-61.
24. Pettegrew J. W., Keshavan M. S., Panchalingam K. A pilot study of the dorsal prefrontal cortex using in vivo phosphorus 31 nuclear magnet resonance spectroscopy. Arch Gen Psychiatr 1991; 48: 563-568.
25. Pettegrew J. W., Keshavan M. S., Minchew N. J. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. Schizophr Bull 1993; 19: 35-53.
26. 31P MRS in schizophrenia. Schizophr Res 1995; 15: 83-84.
27. 2 activity in schizophrenia: a replication study. Biol Psychiatr 1990; 28: 495-501.
28. Hudson C. J., Lin A., Horrobin D. F. Phospholipases: in search of a genetic basis for schizophrenia. This symposium
29. Horrobin D. F. Essential fatty acids, immunity and viral infections. J Nutr Med 1990; 1: 145-151.
30. Koletzko B. Fats for brains. Eur J Clin Nutr 1992; 46 (Suppl 1): 551-562.
31. Pudelkiewicz C., Seufert J., Holman R. T. Requirements of the female rat for linoleic and linolenic acids. J Nutr 1968; 64: 138-147.
32. Huang Y-S., Horrobin D. F., Watanabe Y., Bartlett M. E., Simmons V. A. Effects of dietary linoleic acid on growth and liver phospholipid fatty acid composition in intact and gonadectomized rats. Biochem Arch 1990; 6: 47-54.
33. Christensen O., Christensen E. Fat consumption and schizophrenia. Acta Psychiatr Scand 1988; 78: 587-591.
34. Horrobin D. F. The relationship between schizophrenia and essential fatty acids and eicosanoid production. Prostaglandins Leukotr Essent Fatty Acids 1992; 46: 71-77.
35. Brenner R. R. Nutritional and hormonal factors Influencing desaturation of essential fatty acids. Prog Lipid Res 1982; 20: 41-48
36. Horrobin D. F. Gamma-linolenic acid. Rev Con Pharmacother 1990; 1: 1-41.
37. Horrobin D. F. Nutritional and medical importance of gamma-linolenic acid. Prog Lipid Res 1992; 31: 163-192.
38. 2 release following oral administration of niacin in humans. J Invest Dermatol 1992; 98: 812-815.
39. Myers P. R., Blosser J., Shain W. Neurotransmitter modulation of prostaglandin E1-stimulated increases in cyclic AMP. II. Characterisation of a cultured neuronal cell line treated with dibutyryl cyclic AMP. Biochem Pharmacol 1978; 27: 1173-1177.
40. Schwartz R. D., Uretsky N. J., Bianchine J. R. Prostaglandin inhibition of apomorphine-induced circling in mice. Pharmacol Biochem Behav 1972; 17: 1233.
41. 1. Prostaglandins Med 1981; 7: 267-280.
42. Brus R., Herman Z. S., Szkilnik R., Cichon R. Effect of prostaglandins on chloropromazine induced catalepsy in mice. Biomed Biochim Acta 1983; 42: 1211-1244.
43. Davidson B., Kustiens N. P., Patton J., Cantrill R. C. Essential fatty acids modulate apomorphine activity at receptors in cat caudate slices. Eur J Pharmacol 1988; 149: 317-322.
44. Horrobin D. F. The roles of prostaglandins and prolactin in depression, mania and schizophrenia. Postgrad Med J 1977; 53 (Suppl 4): 160-165.
45. 2 activity in the brain of rats. Eur Arch Psychiatr Clin Neurosci 1995; 245: 179-182.
46. Glen A. I. M., Cooper S. J., Rybakowski J. et al. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukotr Essent Fatty Acids, this issue